In a metastatic prostate cancer model, degarelix versus triptorelin plus antiandrogen had an ICER of £59,000 per QALY gained.
In plain wordsIn a prostate cancer model, degarelix versus triptorelin plus antiandrogen cost £59,000 per additional quality-adjusted life year.
- Outcome
- Not applicableIncremental cost-effectiveness ratio
- Study
n: not reported in source
decision analytic model with a decision tree and Markov model- Comparator
- degarelix
- Outcome group
- Cost-effectiveness · Cancer
Measurements
- ICER
- 59,000 £ per QALY gained
- degarelix versus triptorelin plus antiandrogen
Source sentences
In the base-case analysis, the incremental cost-effectiveness ratio (ICER) for degarelix vs triptorelin plus antiandrogen was £59,000 per QALY gained.
3 context sentences(design, population, supporting numbers)
We developed a decision analytic model based on a clinical trial and literature review.
The two interventions evaluated were: (i) monthly injection of degarelix and (ii) 3-monthly triptorelin therapy plus short-term flutamide, cyproterone or bicalutamide treatment.
The base-case analysis assumed patients present with asymptomatic metastatic prostate cancer.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).